PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial tests PF-08634404 as monotherapy and in combination with chemotherapy in adults whose prior EGFR-mutated NSCLC has transformed to small cell lung cancer. Eligible participants must have at least one measurable lesion, adequate organ function, ECOG performance status 0–1, and generally no prior systemic therapy for the transformed SCLC. The study uses RECIST v1.1 to measure tumor response and requires tumor tissue to confirm transformation and explore biomarkers. The multicenter trial is sponsored by Pfizer and is enrolling at sites in the United States and Japan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participants aged ≥18 years at the time of informed consent.
* Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
* Participants have not received systemic therapy for T-SCLC.
* Have at least one measurable lesion as the target lesion based on RECIST v1.1.
* Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Have a minimum life expectancy of \>12 weeks.
* Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

* Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter \<1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.
* Leptomeningeal disease
* Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
* History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
* Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)
* History of allogeneic organ or hematopoietic stem cell transplantation
* Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
* Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:

  * Prior or current non-infectious pneumonitis requiring systemic therapy
  * DLCO \<50% predicted
  * Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
* Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
* Baseline QTcF \>480 msec
* Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
* Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
* History of significant bleeding disorders or recent major bleeding events
* Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
* Active, uncontrolled, or symptomatic infection, including:

  * Active TB
  * Active hepatitis B or C
  * Uncontrolled HIV infection
* History of immunodeficiency
* Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies
* Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
* Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods
* Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes
* Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)
* Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements

Where it's running

• City of Hope National Medical Center
  Duarte, California, United States Recruiting
• UC San Diego Medical Center - Encinitas
  Encinitas, California, United States Recruiting
• City of Hope Lennar Foundation Cancer Center
  Irvine, California, United States Recruiting
• UC San Diego Koman Family Outpatient Pavilion
  La Jolla, California, United States Recruiting
• UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
  La Jolla, California, United States Recruiting
• UC San Diego Moores Cancer Center
  La Jolla, California, United States Recruiting

+11 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Using a new PFD3 PET tracer to find and stage small cell lung cancer

  This test will try a new PET tracer called PFD3 in adults with small cell lung cancer to see if it detects tumors and stages disease more accurately than standard FDG PET/CT.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing, Beijing Municipality · NCT07508852

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Lurbinectedin with Osimertinib for transformed small cell lung cancer

  This study tests a drug combo (lurbinectedin plus osimertinib) to see if it can help adults whose EGFR-mutated non-small cell lung cancer has transformed into small cell lung cancer.

  Recruiting Phase 1/2 Indiana University · Indianapolis, Indiana · NCT07153055

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.